Total Payments
$221.47
2024 Payments
$79.94
Companies
8
Transactions
12
Medicare Patients
2,830
Medicare Billing
$447,798
Payment Breakdown by Category
Food & Beverage$204.58 (92.4%)
Education$16.89 (7.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $204.58 | 11 | 92.4% |
| Education | $16.89 | 1 | 7.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $58.78 | 4 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $46.80 | 2 | $0 (2024) |
| Vifor Pharma, Inc. | $27.98 | 1 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $21.14 | 1 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.38 | 1 | $0 (2023) |
| Travere Therapeutics, Inc. | $16.89 | 1 | $0 (2024) |
| Abbott Laboratories | $16.25 | 1 | $0 (2017) |
| Mallinckrodt Hospital Products Inc. | $16.25 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $79.94 | 4 | AstraZeneca Pharmaceuticals LP ($46.80) |
| 2023 | $31.65 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($17.38) |
| 2022 | $72.49 | 4 | Horizon Therapeutics plc ($44.51) |
| 2021 | $21.14 | 1 | Otsuka America Pharmaceutical, Inc. ($21.14) |
| 2017 | $16.25 | 1 | Abbott Laboratories ($16.25) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/21/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 05/24/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/03/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: IMMUNOLOGY | ||||||
| 12/14/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: KRYSTEXXA | ||||||
| 11/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: DIABETES | ||||||
| 11/21/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $11.87 | General |
| Category: KRYSTEXXA | ||||||
| 09/08/2022 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Hyperkalemia | ||||||
| 07/13/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: KRYSTEXXA | ||||||
| 03/04/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: KRYSTEXXA | ||||||
| 10/14/2021 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: NEPHROLOGY | ||||||
| 09/26/2017 | Abbott Laboratories | MRI Ready Leads (Device) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 691 | 2,049 | $314,079 | $100,491 |
| 2022 | 10 | 533 | 1,831 | $258,830 | $74,758 |
| 2021 | 9 | 725 | 1,413 | $331,051 | $130,753 |
| 2020 | 10 | 881 | 1,734 | $377,768 | $141,796 |
Total Patients
2,830
Total Services
7,027
Medicare Billing
$447,798
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 226 | 478 | $120,934 | $33,102 | 27.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 157 | 322 | $65,422 | $28,624 | 43.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 83 | 186 | $35,730 | $11,415 | 31.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 71 | 73 | $29,824 | $9,504 | 31.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 52 | 52 | $17,212 | $5,820 | 33.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 12 | 770 | $13,090 | $4,160 | 31.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 32 | $12,376 | $3,055 | 24.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 31 | 72 | $11,448 | $2,774 | 24.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 19 | $6,783 | $1,632 | 24.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 45 | $1,260 | $405.10 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 261 | 534 | $135,054 | $37,312 | 27.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 67 | 67 | $24,049 | $7,888 | 32.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 53 | 147 | $30,471 | $7,835 | 25.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 45 | 89 | $18,482 | $7,091 | 38.4% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2022 | 15 | 870 | $14,790 | $5,618 | 38.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $8,776 | $2,864 | 32.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 18 | $6,426 | $1,997 | 31.1% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 23 | 36 | $13,530 | $1,973 | 14.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 18 | $6,328 | $1,832 | 29.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 16 | 33 | $924.00 | $349.15 | 37.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 241 | 481 | $114,478 | $43,748 | 38.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 168 | 459 | $91,598 | $38,093 | 41.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 85 | 87 | $33,714 | $13,721 | 40.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 84 | 195 | $27,220 | $11,230 | 41.3% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 12 | 41 | $24,067 | $9,411 | 39.1% |
About Dr. Muhammad Uddin, MD
Dr. Muhammad Uddin, MD is a Nephrology healthcare provider based in Mesa, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1396936373.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Muhammad Uddin, MD has received a total of $221.47 in payments from pharmaceutical and medical device companies, with $79.94 received in 2024. These payments were reported across 12 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($204.58).
As a Medicare-enrolled provider, Uddin has provided services to 2,830 Medicare beneficiaries, totaling 7,027 services with total Medicare billing of $447,798. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Mesa, AZ
- Active Since 08/06/2007
- Last Updated 07/15/2019
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1396936373
Products in Payments
- KRYSTEXXA (Biological) $58.78
- FARXIGA (Drug) $46.80
- Veltassa (Drug) $27.98
- JYNARQUE (Drug) $21.14
- JARDIANCE (Drug) $17.38
- ACTHAR (Biological) $16.25
- MRI Ready Leads (Device) $16.25
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Mesa
Mandeep Sahani, Md, MD
Nephrology — Payments: $10,811
Nephrology $10,811
Kenneth Boren, M.d, M.D
Nephrology — Payments: $10,588
Nephrology $10,588
Fredrick Osorio, M.d, M.D
Nephrology — Payments: $4,175
Nephrology $4,175
Sanjay Lamba, M.d, M.D
Nephrology — Payments: $3,334
Nephrology $3,334
Dr. Bindu Jayavelu, M.d, M.D
Nephrology — Payments: $3,333
Nephrology $3,333
Lance Bechtold, Md, MD
Nephrology — Payments: $2,988
Nephrology $2,988